Market revenue in 2023 | USD 641.3 million |
Market revenue in 2030 | USD 886.4 million |
Growth rate | 4.7% (CAGR from 2023 to 2030) |
Largest segment | Biopharmaceuticals |
Fastest growing segment | Biopharmaceuticals |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Pharmaceuticals, Biopharmaceuticals |
Key market players worldwide | Boehringer Ingelheim, Novartis AG ADR, Regeneron Pharmaceuticals Inc, Pfizer Inc, Bristol-Myers Squibb Co, Roche Holding AG, UCB SA, Johnson & Johnson, Amgen Inc, AbbVie Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to rheumatoid arthritis therapeutics market will help companies and investors design strategic landscapes.
Biopharmaceuticals was the largest segment with a revenue share of 88.73% in 2023. Horizon Databook has segmented the Italy rheumatoid arthritis therapeutics market based on pharmaceuticals, biopharmaceuticals covering the revenue growth of each sub-segment from 2018 to 2030.
The Italy rheumatoid arthritis therapeutics market is influenced by significant corporate acquisitions and global market dynamics. A key recent development is the acquisition of Horizon Therapeutics by Amgen in December 2022, which is expected to bolster the rheumatology sector in Italy.
Amgen's acquisition of Horizon Therapeutics, facilitated through the newly formed private company Pillartree Limited, was valued at USD 28.5 billion. This substantial acquisition indicates the growing interest and investment in the rheumatology sector and may lead to downstream effects that reshape the market landscape in Italy.
For the acquisition to proceed, antitrust clearances are required in several European countries, including Italy, along with foreign investment clearances in Italy, Denmark, France, and Germany. These regulatory processes highlight the importance of compliance and adherence to market regulations, ensuring that the acquisition does not hinder competition or restrict patient access to essential RA treatments.
Horizon Databook provides a detailed overview of country-level data and insights on the Italy rheumatoid arthritis therapeutics market, including forecasts for subscribers. This country databook contains high-level insights into Italy rheumatoid arthritis therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account